{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.31","value":"-12.5"},{"groupId":"OG001","spread":"13.30","value":"-10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"A Rheumatologist or an skilled arthritis assessor evaluated 66 joints at baseline and at Week 48. A negative change from baseline in Swollen Joint Count indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Retreatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Retreatment"}],"paramType":"MEAN","populationDescription":"Intent-to-treat population includes all participants randomized to Retreatment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Change From Baseline in American College of Rheumatology (ACR) Core Set Component: Swollen Joint Count at Week 48","type":"SECONDARY","unitOfMeasure":"Joint Count"}